Titus Thorne

Last Updated March 16, 2023

Titus Thorne

 March 16, 2023

Curious about the use of BPC-157 and treat erectile dysfunction?

If you answered yes, then you have come to the right place!

This ultimate guide will provide you with the most important information available on the application of BPC-157 in the context of erectile dysfunction treatment. We will explain:

  • What is BPC-157?
  • BPC-157 and Erectile Dysfunction
  • BPC-157 Benefits
  • BPC-157 Safety

To add, we will offer you our expert recommendation for purchasing the best BPC-157 available online.

Dive in to explore all you need to know about BPC-157, including data from cutting-edge, peer-reviewed studies and how to successfully incorporate this popular peptide into your research on erectile dysfunction.

Buy BPC-157 from the #1 online Peptides vendor in the world...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

What is BPC-157?

BPC-157 (Body Protection Compound-157), also known as bepecin, is a synthetic peptide that is evidenced to have a range of therapeutic effects.

A derivative of the naturally occurring gastric protein called Body Protection Compound (BPC), BPC-157 is classed as a pentadecapeptide. BPC is found in the gastrointestinal tract and is vital to digestive function, strengthening and healing lesions in the GI lining. It is also shown to promote angiogenesis, cellular repair, and tissue growth in many organs while modulating inflammatory response [1, 2, 3].

Therapeutic Prospects

BPC-157 is more stable than endogenous BPC and exhibits therapeutic properties without the need for a carrier agent. While the primary action of BPC is in the digestive tract, where it heals and protects the GI lining, BPC-157 is linked in clinical studies to benefits in multiple organ systems. Its systemic effects are primarily attributed to its stimulation of angiogenesis and fibroblast proliferation.

Particular benefits of BPC-157 include improved healing in many types of tissue, such as vascular, hepatic, and nervous. This indicates the peptide’s potential to address symptoms of cardiovascular and neurodegenerative diseases. It is also shown to facilitate regeneration in bone, tendon, and muscle tissues. Lastly, BPC-157 exhibits potent antioxidant properties not just in the GI tract but globally, suggesting its prospective utility in the context of inflammatory disease treatment [2, 3, 4, 5, 6].


BPC-157 was initially synthesized in the early 1990s and studied for its cytoprotective properties as an anti-ulcer agent. Although it entered phase 1 trials in consideration as a treatment of ulcerative colitis, it has not been approved by the US Food and Drug Administration (FDA) for medical use, and data on human subjects is lacking. However, wide research in animal models to date suggests that BPC-157 is safe and well-tolerated when properly administered [16].

It is one of the several in-demand research peptides that are prized for their healing and regenerative effects. TB-500 is also similarly under investigation for its angiogenic and reparative properties. Traditionally injected, both TB-500 and BPC-157 have seen recent advances to increase their stability and oral bioavailability, potentially augmenting their therapeutic applications and marketing appeal [7, 8].

Now…let us take a look at what, if anything, BPC-157 peptide can do in cases of erectile dysfunction.

BPC-157 Erectile

BPC-157 and Erectile Dysfunction

Erectile dysfunction is attributable to several different causes, classified as vasculogenic, psychogenic, endocrinologic, or neurologic. Treatment is typically prescribed according to the underlying cause. However, currently available drugs fall short in some cases, prompting clinicians to search for therapeutic alternatives [9].

Vasculogenic ED

Researchers have long noted the common co-occurrence of ED and cardiovascular or metabolic diseases. Indeed, recent literature advises practitioners to consider ED as an early warning sign of these diseases. Vasculogenic ED in particular is linked with arterial and endothelial damage, often attributed to systemic inflammation.

Among vasculogenic ED patients, traditional ED treatments such as selective PDE5 inhibitors, which act on the penile musculature via the NO system, often fail to elicit long-term therapeutic outcomes in subjects with severe cardiovascular and metabolic disease. Other current treatments such as penile injections function to temporarily increase penile blood flow, a transient solution at best [10, 11, 12].

As such, researchers in the nascent field of regenerative medicine have begun to study alternative ED treatments that consider the roles of angiogenesis, vascular insufficiency, and endothelial dysfunction in the disease. In one study on rat models, cytokine therapy designed to promote angiogenesis and stimulate endothelial growth was proven to effectively treat ED. Another animal study showed that the administration of vascular growth factors led to penile neovascularization, a possible long-term solution to vasculogenic ED [13, 14].

Further novel treatments include lasting modulation through gene therapy of the NO system, which affects penile musculature to enable erectile response. This is considered a favorable alternative to orally bioavailable PDE5 inhibitors that show poor results in subjects with acute metabolic disease [10, 15, 16].

Studies on BPC-157 and Erectile Dysfunction

Despite the ready applicability of BPC-157 in therapeutic contexts such as angiogenesis, endothelial growth, and regulation of the inflammatory response, no studies to date have been specifically conducted on its use in ED patients.

However, the handful of studies available is promising. BPC-157 was shown in rat models to combat heart failure via the NO system, echoing emerging gene therapy modalities in ED treatment. Another study on diabetes-related ED in rats indicated the potential of NO modulation to successfully improve erectile response [10, 17, 18].

Furthering the scope of BPC-157’s potential benefits in ED treatment, it is ripe for synergistic combination with other traditional and emerging treatments. For example, its regenerative and angiogenic effects may aid therapies involving nerve reconstruction and penile transplants of muscle or cartilage tissues. Optimistically, its benefits may preclude the need for surgical intervention altogether. However, barring further research, this remains a speculatory point [11].

In short, BPC-157 shows great promise as a treatment for ED, particularly as a solution to current shortcomings in ED pharmacology regarding vascular etiologies.

BPC-157 Benefits

There is great evidence to support the therapeutic effects of BPC-157 in numerous contexts.

While extensive trials in human subjects are lacking, studies to date in both animal and human models are highly favorable. Here is a quick review of the most notable benefits of BPC-157:

Gastrointestinal Health

BPC-157, like its endogenous counterpart, has potent cytoprotective properties, shown to fortify the lining of the GI tract while healing and preventing lesions. As an anti-ulcer agent, it is likely effective in the treatment of inflammatory bowel disease. It is also shown in animal models to bolster biochemical feedback mechanisms along the gut-brain axis [2, 4, 22].

Injury Recovery

The regenerative effects of BPC-157 have been widely documented in animal models, showing improved healing in bone, skin, ligaments, and muscles, among other tissue types. This is attributed to its increase in fibroblast proliferation [3, 22].


BPC-157 is further proven in animal studies to prompt vascular growth through increases in endothelial growth factor. This process contributes to injury and wound healing and may greatly benefit cardiovascular health, boosting circulation and normalizing blood pressure. Per the discussion above, this also has implications in the treatment of vasculogenic ED [11, 23, 24].

Neurological Health

With neuroprotective properties, BPC-157 is shown in animal models to reduce damage due to central nervous system injuries and strokes. It is also evidenced to balance neurotransmitter levels, potentially addressing symptoms of Parkinson’s disease, schizophrenia, and depression [2, 6, 11].

Reduces Drug Toxicity

BPC-157 may protect against the toxic effects of certain drugs, such as neuroleptics, alcohol, NSAIDs, and insulin. Protective benefits are evidenced in the liver, GI tract, cardiovascular system, and nervous system [6, 11, 25].

Improved Inflammatory Response

The anti-inflammatory properties of BPC-157 have been well-documented and observable in various tissue types, including the lungs, liver, GI tract, and brain [11, 23].

Emerging investigations indicate that BPC-157 may also aid in collagen synthesis and pain relief [26, 27].

Is BPC-157 Safe?

Due to a lack of clinical trials, there is a shortage of data on the safety of BPC-157 for use in humans. However, research to date suggests a positive safety profile. In humans and animals, it has shown no toxicity and good tolerability [23, 28].

However, researchers should exercise caution in the administration of BPC-157. It is occasionally known to cause transient and mild adverse effects, such as [6]:

  • Injection site irritation
  • Nausea
  • Fatigue
  • Sweating
  • Light-headedness

To minimize the risk of adverse effects, researchers are advised to purchase peptides from legitimate suppliers and adhere to established clinical guidelines concerning proper handling.

Looking to learn more about BPC-157 side effects? Just click here.

BPC-157 Erectile

Where to Buy BPC-157 Online | 2023 Guide

In light of the exciting potential of BPC-157, it is an excellent addition to clinical research on effective ED treatments. When adding this popular peptide to your toolbox, it is a must that you purchase from a legitimate vendor.

As such, the passionate experts at Peptides.org have scoured the net to give you our number-one recommendation for buying premium BPC-157 online:

Peptide Sciences

Why is Peptide Sciences the leading supplier for scientists around the world?

  • Fast, Dependable Shipping: Peptide Sciences ships peptides to U.S. addresses within 2-3 business days and internationally within 7-10 business days. They waive all shipping fees on US orders over $200. When our team made a small test order of BPC-157, it arrived promptly without issues.
  • Friendly Customer Service Team: Our inquiries were answered within 48 hours and we received useful information from the staff at Peptide Sciences.
  • Convenient Payment Options: Peptide Sciences accepts all major credit cards. In addition, they offer individual and wholesale pricing, should researchers prefer to make bulk purchases.
  • Third-Party Testing: Unique among the peptide vendors that we tested, Peptide Sciences gets every batch of peptides tested by an independent lab and posts the lab reports online. This increases transparency and helps build trust. Peptide Sciences has partnered with WHO/GMP and ISO 9001:2008-approved manufacturers, and only sources their products domestically in the United States.

Buy BPC-157 from our #1 recommended vendor...

Bacteriostatic Water and Injections

BPC-157 is often sold as a lyophilized powder that requires reconstitution with a sterile solvent to be injected. Scientists tend to agree that bacteriostatic water is the best solvent for this purpose.

What is Bacteriostatic Water?

Composed of sterile water and a natural preservative called benzyl alcohol, bacteriostatic water resists bacterial proliferation to combat contamination. It has an extended shelf life and efficiently dissolves lyophilized peptides while maintaining their purity [19, 20, 21].

Supplies Needed

The correct method of BPC-157 reconstitution calls for the following materials:

  • Vial of bacteriostatic water
  • Vial of lyophilized MT-I
  • Sterile syringe
  • Alcohol wipes
  • Extra sterile vials are recommended

Reconstitution Process

Follow this procedure to reconstitute lyophilized BPC-157 for injection:

  • Step #1: Wipe all materials with the alcohol swabs to reduce the risk of contamination.
  • Step #2: Using the sterile syringe, withdraw the desired amount of bac water, typically around 1mL.
  • Step #3: Slowly inject the bac water into the vial of BPC-157, allowing the powder to gradually dissolve.
  • Step #4: Refrain from agitating the vial, as this may damage the contents. When the solution is fully mixed, it will appear transparent.
  • Step #5: If the powder does not completely dissolve, you may require a stronger solvent.
  • Step #6: The extra solution may be safely refrigerated and accessed for up to 28 days after reconstitution.
  • Step #7: For precise storage and dosage indications, refer to manufacturer labels.

Buy Bacteriostatic Water from our #1 recommended vendor...

BPC-157 and Erectile Dysfunction | Verdict

To conclude, BPC-157 shows promise in the treatment of erectile dysfunction as an angiogenic, anti-inflammatory, and healing agent.

It may be particularly suited to combating ED caused by underlying cardiovascular problems. While the research to date certainly indicates great potential, BPC-157 has not yet been closely studied in this context.

Researchers can seize this opportunity to conduct innovative studies into the use of BPC-157 as a novel therapy for symptoms of ED.

To attain top-quality BPC-157, visit our top-recommended vendor, Peptide Sciences.


  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019 Aug;377(2):153-159. doi: 10.1007/s00441-019-03016-8. Epub 2019 Mar 27. PMID: 30915550.
  2. Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969. PMID: 34380875; PMCID: PMC8504390.
  3. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. doi: 10.3390/molecules191119066. PMID: 25415472; PMCID: PMC6271067.
  4. Sikiric P, Drmic D, Sever M, Klicek R, Blagaic AB, Tvrdeic A, Kralj T, Kovac KK, Vukojevic J, Siroglavic M, Gojkovic S, Krezic I, Pavlov KH, Rasic D, Mirkovic I, Kokot A, Skrtic A, Seiwerth S. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des. 2020;26(25):2991-3000. doi: 10.2174/1381612826666200424180139. PMID: 32329684.
  5. Krivic, A., Anic, T., Seiwerth, S., Huljev, D. and Sikiric, P. (2006), Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation. J. Orthop. Res., 24: 982-989. https://doi.org/10.1002/jor.20096
  6. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Rak D, Dzidic S, Vrcic H, Sebecic B. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. doi: 10.2174/13816128130111. PMID: 22950504.
  7. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012 Jan;12(1):37-51. doi: 10.1517/14712598.2012.634793. Epub 2011 Nov 10. PMID: 22074294.
  8. US9850282B2 – stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy [Internet]. Google Patents. Google; [cited 2023Jan]. Available from: https://patents.google.com/patent/US9850282B2/en
  9. K.-E. Andersson. Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction. Pharmacological Reviews December 1, 2011, 63 (4) 811-859; DOI: https://doi.org/10.1124/pr.111.004515
  10. Carneiro, F. S., Webb, R. C., & Tostes, R. C. (2010). Emerging Role for TNF-α in Erectile Dysfunction. The journal of sexual medicine, 7(12), 3823. https://doi.org/10.1111/j.1743-6109.2010.01762.x
  11. Williams, Steve K. et al.Novel therapeutic targets for erectile dysfunction. Maturitas, Volume 71, Issue 1, 20 – 27.
  12. Beckman, Thomas J. et al. Evaluation and Medical Management of Erectile Dysfunction
    Mayo Clinic Proceedings, Volume 81, Issue 3, 385 – 390
  13. Hakim L, Van der Aa F, Bivalacqua TJ, Hedlund P, Albersen M. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol. 2012 Sep;9(9):520-36. doi: 10.1038/nrurol.2012.143. Epub 2012 Jul 24. PMID: 22824778.
  14. Ti YR, Xiao DD, Lu MJ. [Updated cytokine therapy of erectile dysfunction]. Zhonghua Nan Ke Xue. 2019 Jul;25(7):660-663. Chinese. PMID: 32223111.
  15. Gigante A, Navarini L, Margiotta D, Barbano B, Afeltra A, Rosato E. Erectile dysfunction: Imbalance between pro-angiogenic and anti-angiogenic factors in systemic sclerosis. Eur J Intern Med. 2018 Jul;53:e17-e18. doi: 10.1016/j.ejim.2018.04.017. Epub 2018 Apr 24. PMID: 29699724.
  16. Siroky MB, Azadzoi KM. Vasculogenic erectile dysfunction: newer therapeutic strategies. J Urol. 2003 Aug;170(2 Pt 2):S24-9; discussion S29-30. doi: 10.1097/01.ju.0000075361.35942.17. PMID: 12853769.
  17. Balenovic D, Bencic ML, Udovicic M, Simonji K, Hanzevacki JS, Barisic I, Kranjcevic S, Prkacin I, Coric V, Brcic L, Coric M, Brcic I, Borovic S, Radic B, Drmic D, Vrcic H, Seiwerth S, Sikiric P. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regul Pept. 2009 Aug 7;156(1-3):83-9. doi: 10.1016/j.regpep.2009.05.008. Epub 2009 May 22. PMID: 19465062.
  18. Soni SD, Song W, West JL, Khera M. Nitric oxide-releasing polymeric microspheres improve diabetes-related erectile dysfunction. J Sex Med. 2013 Aug;10(8):1915-25. doi: 10.1111/jsm.12216. Epub 2013 Jun 10. PMID: 23751157.
  19. W. B. What is Bacteriostatic Water? [Internet]. Study.com | Take Online Courses. Earn College Credit. Research Schools, Degrees & Careers. 2022 [cited 2022Aug17]. Available from: https://study.com/academy/lesson/what-is-bacteriostatic-water-definition-uses.html
  20. Bacteriostatic Water for Injection [Internet]. Drugs.com. 2021 [cited 2022Aug17]. Available from: https://www.drugs.com/pro/bacteriostatic-water-for-injection.html
  21. Jackson S. The complete guide on Bacteriostatic Water [Internet]. MedLab International. MedLab International; 2019 [cited 2022Aug17]. Available from: https://medlabgear.com/blogs/articles/guide-bacteriostatic-water
  22. Biomedicines [Internet]. Biomedicines | Special Issue : Frontiers in Pentadecapeptide BPC 157. [cited 2022Dec17]. Available from: https://www.mdpi.com/si/84378
  23. SA; D. BPC 157 as potential treatment for covid-19 [Internet]. Medical hypotheses. U.S. National Library of Medicine; [cited 2022Dec17]. Available from: https://pubmed.ncbi.nlm.nih.gov/34798584/
  24. Knezevic M, Gojkovic S, Krezic I, Zizek H, Malekinusic D, Vrdoljak B, Vranes H, Knezevic T, Barisic I, Horvat Pavlov K, Drmic D, Staroveski M, Djuzel A, Rajkovic Z, Kolak T, Kocman I, Lovric E, Milavic M, Sikiric S, Tvrdeic A, Patrlj L, Strbe S, Kokot A, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines. 2021 May 26;9(6):609. doi: 10.3390/biomedicines9060609. PMID: 34073625; PMCID: PMC8229949.
  25. Sikiric, P., Seiwerth, S., Rucman, R., Kolenc, D., Vuletic, L. B., Drmic, D., Grgic, T., Strbe, S., Zukanovic, G., Crvenkovic, D., Madzarac, G., Rukavina, I., Sucic, M., Baric, M., Starcevic, N., Krstonijevic, Z., Bencic, M. L., Filipcic, I., Rokotov, D. S., . . . Vlainic, J. (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology, 14(8), 857-865. https://doi.org/10.2174/1570159X13666160502153022
  26. Huang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Shu, Z., Mu, N., Gu, J., Zhang, W., Wang, Y., Zhang, Y., & Zhang, W. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy, 9, 2485-2499. https://doi.org/10.2147/DDDT.S82030
  27. SikiriĆ, P., Gyires, K., Seiwerth, S. et al. The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology 2, 121–127 (1993). https://doi.org/10.1007/BF02659088
  28. Strinic D, Belosic Halle Z, Luetic K, Nedic A, Petrovic I, Sucic M, Zivanovic Posilovic G, Balenovic D, Strbe S, Udovicic M, Drmic D, Stupnisek M, Lovric Bencic M, Seiwerth S, Sikiric P. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life Sci. 2017 Oct 1;186:66-79. doi: 10.1016/j.lfs.2017.08.006. Epub 2017 Aug 7. PMID: 28797793.

Table of Contents
    Add a header to begin generating the table of contents